RAHAT ALI¹, AFTAB ALAM², SATYENDRA K. RAJPUT³, RAZI AHMAD^4,*

BIOCELL, Vol.46, No.12, pp. 2681-2694, 2022, DOI:10.32604/biocell.2022.021224 - 10 August 2022

Abstract Parkinson’s disease (PD) is an age-related neurodegenerative ailment that affects dopamine-producing neurons in a specific area of the brain called the substantia nigra of the ventral midbrain. It is clinically characterized by movement disorder and marked with unusual synaptic protein alpha-synuclein accumulation in the brain. To date, only a few Food and Drug Administration (FDA) approved drugs are available on the market for the treatment of PD. Nonetheless, these drugs show parasympathomimetic related adverse events and remarkably higher toxicity; hence, it is important to find more efficacious molecules to treat PD. In our study, We… More >

EMILIA MANOLE^1,2,#, LAURA DUMITRESCU^2,3,#, CRISTINA NICULIȚE^1,3, BOGDAN OVIDIU POPESCU^1,2,3, LAURA CRISTINA CEAFALAN^1,3,*

BIOCELL, Vol.45, No.1, pp. 1-16, 2021, DOI:10.32604/biocell.2021.013452 - 26 January 2021

Abstract An increasing number of studies provide evidence for the existence of a microbiota-gut-brain axis and its potential involvement in the development of sporadic Parkinson’s disease and other neurodegenerative conditions. The neuropathologic hallmark of Parkinson’s disease is the presence of brain intraneuronal aggregates of misfolded alpha-synuclein, known as Lewy bodies. Some gut microbiota products may trigger alpha-synuclein conformational changes in the neurons of the enteric nervous system, which can then spread to the brain in a prion-like fashion through the vagus nerve. Others may interfere with neuroinflammatory pathways and susceptibility to neurodegeneration. In this review, we More >